HARBIN GLORIA PHARMACEUTICALS Co., LTD (002437.SZ)
- Previous Close
2.9200 - Open
2.9500 - Bid 2.8900 x --
- Ask 2.9000 x --
- Day's Range
2.8500 - 2.9800 - 52 Week Range
1.6600 - 3.1100 - Volume
263,167,148 - Avg. Volume
94,124,244 - Market Cap (intraday)
6.513B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
26.36 - EPS (TTM)
0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 28, 2019
- 1y Target Est
3.23
Harbin Gloria Pharmaceuticals Co., Ltd engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd was founded in 2000 and is based in Harbin, the People's Republic of China.
www.gloria.cc2,703
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 002437.SZ
Afficher davantagePerformance Overview: 002437.SZ
Trailing total returns as of 6/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Comparer à: 002437.SZ
Sélectionnez cette option pour analyser des sociétés comparables en utilisant des indicateurs de performances clés ; sélectionnez jusqu'à 4 actions.
Statistics: 002437.SZ
Afficher davantageValuation Measures
Market Cap
6.56B
Enterprise Value
6.03B
Trailing P/E
27.36
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.75
Price/Book (mrq)
3.37
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
20.71
Financial Highlights
Profitability and Income Statement
Profit Margin
10.03%
Return on Assets (ttm)
4.26%
Return on Equity (ttm)
13.03%
Revenue (ttm)
2.4B
Net Income Avi to Common (ttm)
240.73M
Diluted EPS (ttm)
0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
602M
Total Debt/Equity (mrq)
3.72%
Levered Free Cash Flow (ttm)
205.73M